Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

Fractyl Health (Nasdaq: GUTS), a clinical-stage metabolic therapeutics company focused on obesity and type 2 diabetes, announced it will report its second quarter 2026 financial results and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.

Rhea-AI Summary

Fractyl Health (Nasdaq: GUTS), a clinical-stage metabolic therapeutics company focused on obesity and type 2 diabetes, announced it will report its second quarter 2026 financial results and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.

According to Fractyl Health, investors and the public can access a live webcast of the conference call and presentation in the “Events” section of its investor relations website at http://ir.fractyl.com. The webcast will be archived for replay after the live event.

Argus Aug 4 session 1 alert

+1.15% close to close 3.60K volume Open Argus

Details

News Market Reaction – GUTS

-2.1% Trough Tracked

$115.06M Market Cap

In the Aug 4 session, GUTS gained 1.15%, reflecting a mild positive market reaction. Argus tracked a trough of -2.1% from its starting point during tracking.

Data tracked by StockTitan Argus on the day of publication.

Market Context

-0.2% was the prior 24-hour reaction to Fractyl Health’s comparable earnings-date announcement. The ...

Analysis

-0.2% was the prior 24-hour reaction to Fractyl Health’s comparable earnings-date announcement. The current release only schedules Q2 2026 results; the historical match supplies context, while low short positioning and recent Net Buying frame the risk review.

Key Figures

Reporting period: Q2 2026 Report date: August 10, 2026 Conference time: 4:30 p.m. ET

Reporting period

Q2 2026

Financial results to be reported

Report date

August 10, 2026

Scheduled results announcement

Conference time

4:30 p.m. ET

Scheduled webcast and presentation

Previous Earnings date Reports

1 past event · Latest: Mar 17

Same Type 1 event

1. Mar 17

   Earnings date

   24h Move

   -0.2%

   Prior announcement scheduled fourth-quarter and full-year 2025 results for March 24, 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

t2d

1 terms

t2d medical

"treat obesity and type 2 diabetes (T2D)"

t2d is shorthand for type 2 diabetes, a common chronic condition in which the body struggles to use insulin properly, causing high blood sugar over time. Investors watch t2d because it represents a large, ongoing market for medicines, devices and care—like a steady stream of customers needing better treatments—so clinical trial results, approvals or new therapies can materially affect healthcare company revenues and stock values.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.

A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.

About Fractyl Health        

Fractyl Health is a clinical-stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. Fractyl’s goal is to advance metabolic disease treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.

Contact 

Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Fractyl Health (Nasdaq: GUTS) report its Q2 2026 financial results?

Fractyl Health will report its Q2 2026 financial results on Monday, August 10, 2026, at 4:30 p.m. ET. According to Fractyl Health, this event will also include business updates via a webcasted conference call.

How can investors listen to Fractyl Health's Q2 2026 earnings webcast for GUTS stock?

Investors can access the live Q2 2026 earnings webcast in the “Events” section of Fractyl Health’s investor relations website at http://ir.fractyl.com. According to Fractyl Health, the webcast will cover financial results and business updates.

Will Fractyl Health provide a replay of the August 10, 2026 Q2 2026 earnings call?

Yes, Fractyl Health will archive the August 10, 2026 Q2 2026 webcast for replay. According to Fractyl Health, the replay will be available on its investor relations website following the live event for later on-demand access.

What type of company is Fractyl Health (GUTS) that is reporting Q2 2026 results?

Fractyl Health is a clinical-stage metabolic therapeutics company focused on novel approaches to treat obesity and type 2 diabetes. According to Fractyl Health, the Q2 2026 call will cover financial results and related business updates.

What time does Fractyl Health's August 10, 2026 Q2 2026 conference call start?

Fractyl Health’s Q2 2026 conference call and webcast will start at 4:30 p.m. Eastern Time on August 10, 2026. According to Fractyl Health, the event will present quarterly financial results and business updates.